Partially purified antibody specific to the antitumor, 0-6 branched jHl -+3)-D-glucan (VVG), isolated from the cold alkali-extract of the fruiting body of Volvariella volvacea (Fukurotake) was obtained by immunization of rabbits with the conjugate of VVGwith bovine serum albumin (BSA). Hapten inhibition studies of the precipitation reaction of the antibody and the j?-D-glucan with various
However, the mechanism of their antitumor action has not been completely elucidated.
In previous papers, we reported that a branched;/?-(! -^3)-D-glucan, obtained by cold alkali-extraction of Fukurotake, the fruiting 1849 body of Volvariella volvacea, had a potent antitumor activity against both allogeneic and syngeneic tumors in mice.5 6) This antitumor glucan was further purified and its fine structural feature has been elucidated by chemical and enzymic studies.7* In the course of investigations on the mechanism of immunomodulating action of the glucan, we became aware that, when 3H-labeled glucan-polyol was mtraperitoneally administered to tumorbearing mice, the radioactivities appeared in the serum, 12~23hr after the injection, and the serum contained a tumor-inhibiting factor.^C oncerning the nature of the tumorinhibiting factor and its possible role in the immunomodulating mechanism, this finding
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has prompted us to prepare antibodies specific to the branched /?-(l ->3)-D-glucan. It may also be interesting to clarify the immunochemical specificities of the anti-glucan antibody, in view of fungal infections. This paper reports the preparation of antibodies to the antitumor, branched /?-(1 -»3)-dglucan of V. volvacea, and to the corresponding glucan-polyalcohol by immunization of rabbits with the polysaccharide-protein conjugates, and their immunochemical binding specificities.
This work has also been concerned with use of an immunoadsorbent column of anti-glucan antibody for examination of the nature of the tumor-inhibiting factor formed in the serum.
Materials and Methods

Materials.
The cold alkali-extracted glucan of Fukurotake, the fruiting body of Volvariella volvacea, was purified in the manner described previously. 0.5 him sodium periodate (2.1 mg in 20ml water) at 5°C for 5 days in the dark. After oxidation, ethylene glycol (0.5 ml) was added to decompose the excess periodate, and the solution was dialyzed against distilled water. An aqueous solution of bovine serum albumin (BSA, 5ml, 17mg/ml) was added to the non-dialyzable solution (24ml) containing the oxidized glucan, the mixture being stirred at pH 9.5 and 5°C for 5 days. After the coupling reaction, sodium borohydride (1.9mg) was added to the reaction mixture, the reaction being allowed for 18hr at pH 9.0 and 5°C. Hydrochloric acid was added to destroy the excess borohydride, and the solution was dialyzed. Non-dialyzed material was centrifuged, and the water-insoluble fraction was washed four times with distilled water and lyophilized (yield, 20.9 mg juvant (Difco Lab., Detroit, U.S.A.). A total 2ml of an emulsion containing the antigen (1.5 mg/ml, saline) was injected subcutaneously in the back of the rabbit, weekly for five successive weeks. The blood was taken one week after the last injection and antiserum was obtained.
Immunodiffusion assay. The anti-VVG-BSA serum (10/zl) was placed on the center well in an agar plate. VVG-BSA conjugate, VVG, and BSA (10-25^1, each) were placed in the peripheral wells. The plates were kept at 5°C for 24~72hr.
Quantitative precipitation assay. The quantitative precipitation reaction was done by a modification of Kabat and Mayer's method,15) using small centrifuge tubes (size, 1.5 ml). The glycoconjugate (5~100/ig), polysaccharide
BSA (6~100//g) dissolved in 100/il of 0.05 mborate buffered saline, pH 7.9 (BBS), were added to the tubes containing 20/il of the anti-VVG-BSA serum.
The tubes were incubated at 4°C for 4 days, centrifuged, and washed three times with 600fi\ of cold saline. The washed precipitates were dissolved in 330fA of 0.05m NaOH,and the protein was measured by the Lowry method.
Partial purification of antibody. To remove the antibody to BSA, the anti-VVG-BSA serum was put onto a BSASepharose 4B column (1.5 x 6cm) equilibrated with 0.05 m BBS.Four ml of the antiserum was put on the column. Unadsorbed antibody fractions were eluted with the same 1851 buffer, and the protein fraction containing anti-VVG antibody was collected. Elution from the column with 0. 17 m glycine-HCl buffer, pH 2.4, gave the column-bound anti-BSA antibody protein. The anti-VVG antibody fraction was concentrated to 4ml by ultra filtration, and the partially purified antibody, so obtained, was used for the immunochemical studies.
Similar procedures were used to remove the anti-BSA antibody from anti-VVG polyol-BSA serum. The partially purified anti-VVG polyol antibody (10 ml), free from antiBSAantibody, was further fractionated on a column of DEAE-Sephacel (2.2 x25cm) equilibrated with 0.06m phosphate buffer, pH 7.8. The purified anti-VVG polyol antibody fraction was obtained from the unadsorbed fraction, and was concentrated to 2.6ml.
Hapten inhibition test. The hapten inhibition tests were done as follows: mixtures containing the partially purified antibody (20/zl) and the inhibitor (70/il) at different concentrations were incubated for 1 hr at room temperature. VVGsolution (30/^1, 100/ig) was added to the mixture. After standing at 4°C for 4 days, the precipitated proteins were measured by the Lowry method. Percent inhibitions were expressed as the difference of the amounts of the precipitated proteins with and without inhibitors.
Preparation of affinity column ofanti-VVGantibody. The partially purified anti-VVG antibody (10 ml) was dialyzed against 0.06m phosphate buffer, pH 7.8, and then chromatographed on a column of DEAE-Sephacel (2.2x 25 cm). The column was washed with the starting buffer of 0.06m phosphate at pH 7.8 and followed with a salt gradient up to 0.4m NaCl in the same buffer. The anti-VVG antibody fraction was obtained as the fraction unadsorbed by the chromatography and was concentrated (5 ml). The anti-VVG antibody (2.8 ml, 77.4mg as protein) was coupled to CNBr-activated Sepharose 4B (4g) by a conventional method.16) The reaction was stopped by the addition of 0.2m glycine to block the residual active groups on the Sepharose 4B. The immunoadsorbent, so prepared, was collected by filtration on a glass filter.
Measurement of the uncoupled anti-VVG antibody in the filtrate showed that 1ml of Sepharose 4B-immunoadsorbent contained 5.4mg of the antibody protein.
Different sera from mice with and without VVGtreatments and tests for their antitumor activities. The serum taken from ICR-JCL mice, whose Sarcoma 180 solid tumor had completely regressed upon intraperitoneal administration of VVG(5mg/kg for 10days), was designated Serum A. Serum B was from the tumor-bearing mice without VVGtreatment. Both Serum A and Serum B were obtained from the mice (each group, 10 mice) 5 weeks after implanting Sarcoma 180 ascites cells. Serum C and Serum D were prepared as follows: Sarcoma 180 ascites cells were implanted into ICR mice at day 0, and, at day 14, the mice were treated with VVGat a dose of 100mg/kg by a single intraperitoneal injection. The blood was taken 16hr after polysaccharide injection, and sera were collected by centrifugation. Serum D was prepared similarly to Serum C, except for no tumor inoculation. Serum E was prepared from the tumor-implanted mice, similarly to Serum C, but mice were injected only with phosphate buffered-saline (PBS), and the sera were taken 16hr after PBS injection. Serum F was prepared similarly to Serum E, except for no tumor inoculation. A part of Serum C was onto a anti-VVG antibodySepharose 4B immunoadsorbent column (1.2x6cm) equilibrated with PBS. The column was eluted with the samebuffer, and the unadsorbed fraction was pooled. Whenno absorbance at 280nmwas observed, the column was washed with 3m NaSCN to elute the adsorbed conjugates. The unadsorbed fraction was concentrated to the original volume to give Serum C-I, Serum D-I, E-I, and F-I were prepared similarly to Serum C-I. Each serum was sterilized by passage on a membranefilter (Acrodisc, Gelman Sciences Inc., MI, U.S.A., 0.2jum) and a sample (0.2 ml) was injected intravenously into the tumor-bearing mice (two weeks after 6 x 106 cells ofSarcoma 180 implantation; average tumor volume, 1.1 ml), and the activity for the tumor-growing inhibition was assayed. Mice in a control group were injected with O.2ml of saline. All tested mice were killed 3 weeks after serum injection and the tumors were removed and weighed. The tumor-growth inhibition ratio was calculated by the following equation:
where A is the average tumor weight of the control group and B is that of the treated group. These experimental procedures are illustrated in Scheme 1.
Results and Discussion Preparation of VVG-BSA and VVGpolyol-BSA conjugate, and corresponding antisera Since carbohydrate polymers provide specific haptens but generally act as poor antigens when injected into animals, the purified glucan from Fukurotake (VVG;average molecular weight, 1.0 x 106) was conjugated with BSAto polyalcohol (VVGpolyol), the conjugate of VVG polyol and BSA was prepared. The glucan was, first, oxidized completely with periodate to introduce aldehyde groups in the side chains, and 60% of the aldehyde groups were converted into polyol groups by borohydride reduction. The residual aldehyde groups were coupled with BSA, where partially reduced, glucan aldehyde was reacted with BSA followed by reduction, by which free aldehyde groups in the glucan molecule should be converted into polyol groups. Although the original VVGhad low solubility in cold water, the coupling reaction gave two glycoconjugate fractions with regard to watersolubility, 'i.e., the water-soluble and -insoluble VVG-BSAconjugate. The soluble VVG-BSA was purified by gel filtration, while the waterinsoluble conjugate was thoroughly washed with distilled water to remove BSA.Measurements of glucose and protein revealed that the molar ratios of BSA to glucose in the water-soluble, and -insoluble conjugate were 2.5: 1.0 and 2.2: 1.0, respectively. In the case of VVG polyol-BSA conjugate, their ratios were 3.9: 1.0 (water-soluble fraction) and 3.7 : 1.0 (insoluble fraction), respectively.
Rabbits were immunized by subcutaneous injections with emulsion of the insoluble VVGBSAand Freund's complete adjuvant, and the antiserum specific to the branched glucan was obtained. Figure 1 shows an Ouchterlony double diffusion of the antiserum with the soluble VVG-BSA, VVG, and BSA. Besides a fused intense precipitation line between VVG-BSA and BSA,the antiserum gave a faint and fused precipitation line between VVG-BSA and VVG, indicating that the antiserum raised against VVG-BSAcontained both anti-VVG antibody and anti-BSA antibody. Therefore, the antiserum was put onto an immunoadsorbent column of BSA-Sepharose 4B. This partially purified the antibody, free from antibody to BSA. Figure 2 shows the quantitative precipitation curves of the partially purified antibody with VVG-BSA, VVG, and BSA. No precipitation with BSAwas observed, confirming that anti-BSA antibody was removed by a single immunoadsorbent column. At the Laminaran, which is an essentially linear /?-(l->3)-glucan, showed no reactivity to the antibody (data are not shown), supporting the hypothesis that the antibody predominantly recognize the /?-D-glucopyranosyl branching units.
Concerning the cross-reactivity of the related branched glucans, such as SPG, as shown in Table I Antibody specific to glucan polyalcohol The antibody raised against glycoconjugate of the glucan polyalcohol with BSA (VVG polyol-BSA) was prepared and its immunochemical properties were characterized. The antibody fraction obtained from the rabbit serum by chromatography on a BSASepharose column was further fractionated on DEAE-Sephacel. The anti-VVG polyol antibody was obtained from the unadsorbed fraction. Thus, from 38ml of the antiserum put on, we obtained 330mg of antibody protein (3.32 mg/ml). Figure 5 shows the precipitation curves of the antibody with the glycoconjugate, glucan derivatives, and also protein. No precipitation with BSA was observed, indicating that the anti-BSA antibody was completely removed.
VVGpolyol-BSA and VVGpolyol precipi- 19fig of protein was precipitated at the maximum precipitation reaction with VVG (127.0fig).
Although VVG polyol showed a weak reactivity with the anti-VVG antibody, the anti-VVG polyol antibody is capable of interacting with VVG. of various fungi, we attempted to prepare the VVG antibody-conjugated immunoadsorbent columnto examine the immunochemical nature of a tumor-inhibiting factor that appeared in the tumor-bearing mouseserum after intraperitoneal injection of VVG.6) For this purpose, the antibody was further purified using a DEAE-Sephacel column, and the antibody specific to VVGwas obtained from the unadsorbed fraction. By this procedure, 10 ml of the pre-purified antibody fraction yielded 223mg of the antibody, as confirmed by the immunodiffusion analysis. The VVG antibody so obtained was coupled to CNBr-activated Sepharose, to give the corresponding Sepharose immunoadsorbent con- (1 ->3)-glucan. Thus, when aqueous solution of VVG(1 ml, 1 mg/ml) was put onto the column, which had been equilibrated with PBS (pH 7.2), 87.6% of VVGwas adsorbed, and was eluted with 3M NaSCN.
In accordance with the procedure described in Materials and Methods (see Scheme 1), different sera were prepared from Sarcoma 180-bearing or normal mice, with or without intraperitoneal administration of VVG (100 mg/kg), and each mouse serum was taken and assayed for tumor-growth inhibition activity. As listed in Table II , among the sera tested, Serum C obtained from the group of tumor-bearing mice, 16 hr after treatment with VVG (100mg/kg) showed a high antitumor activity on Sarcoma 180 solid tumor (inhibition ratio, 67.6%). Serum D, the serum from the normal mice without tumors, after treatment with VVGin the same way as that for Serum C, had similar activity (inhibition ratio, 70.2%). On the other hand, Serum A, collected from the mice whosetumorswere completely regressed after 5 weeks, by successive administration of VVG (5mg/kg for 10days after tumor inoculation),5} was somewhatless active than Serum C or D (inhibition ratio, 44.4%), but higher than Serum E of the tumor-bearing mice without VVGtreatment. Serum B obtained from the tumor-bearing mice (for 5 weeks after tumor inoculation), like Serum F Prepared by the method shown in Scheme 1.
having no tumor inoculation, showed essentially no antitumor activity.
The above results clearly indicated that the intraperitoneal administration of VVG at a large dose should induce production of a kind of tumor-inhibiting factor in mouse serum. As regards timing for formation of this factor, no difference in the antitumor activity was observed, so far as blood was taken at 10hr to 23 hr after intraperitoneal injection of VVG.
Since the tumor-inhibiting factor found in the serum of mice by administration of VVG would possibly be related to the glucan, as suggested in our previous work using the 3H-labeled VVG polyol (3H-VVG polyol),6) isolation of this factor was attempted using the VVGantibody-Sepharose column. Sera C and D, were put onto the column, and then column pass-through fractions, C-I and D-I, were obtained. It must be noted that Serum C-I and Serum D-I showed significantly lower antitumor activities (inhibition ratios, 22.6% and 27.4%, respectively) than those of original sera, as shown in Table II .
These results indicated that the tumorinhibiting factor must be retained on the immunoadsorbentcolumn, and therefore, have a similar immunochemical nature to VVG.It is not yet possible to say whether the inhibiting factor is the true glucan, or its modified products, e.g., a kind of glucan-protein conjugate formed during tissue circulation. In this connection, whenthe antitumor-active mouseserum, derived by intraperitoneal administration of 3H-VVGpolyol, was examined by liquid chromatography using a MonoQ column, we found that the 3H-labeled, active component was retained on this anion exchange column.6) From this, the possibility of metabolic modification of the glucan cannot be ruled out.
Chemical identification of the inhibiting factor must await a sufficient amountof SerumC. factor formed in mouse serum, they suggested i t to be glycoprotein or protein in nature, although it might not be purified yet.
This study showed that the immunoadsorbent column, conjugated with the antibody to O-6-branched j?-(l -^3)-glucan, provides a useful probe for characterization of the glucan factor. It may be noted that Czop et al.21) recently reported the presence of a receptor for /?-D-glucan on human monocytes, in relation to stimulation of macrophage activities by zymosan. In such investigations, the antibody specific to branched j6-(l->3)-D-glucan may also be applicable to interaction of such a glucan with receptors on cell surfaces.
